A patient with type 1 diabetes on intensive insulin therapy continues to have postprandial spikes despite carbohydrate counting. An injectable non-insulin agent that delays gastric emptying, suppresses glucagon, and promotes satiety is added as an adjunct. This agent is:
- A Exenatide
- B Pramlintide ✓
- C Colesevelam
- D Bromocriptine mesylate
Correct answer: B. Pramlintide
Explanation
Pramlintide is a synthetic analog of amylin, the peptide co-secreted with insulin by beta cells. Amylin slows gastric emptying, suppresses postprandial glucagon secretion, and increases satiety centrally, so pramlintide is approved as an adjunct to mealtime insulin in both type 1 and type 2 diabetes. Exenatide is a GLP-1 agonist used in type 2 diabetes, colesevelam is a bile acid sequestrant, and bromocriptine acts centrally on dopaminergic pathways.
Reference: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.